OTR3
OTR3 is dedicated to regenerative medicine, focusing on innovative therapies using RGTA® (ReGeneraTing Agents) technology. Their mission is to develop and provide advanced solutions for tissue repair, regeneration, and replacement across various medical fields, including wound healing, stroke recovery, and tissue destruction treatment. They aim to improve patient outcomes through cutting-edge research and clinical applications.
Industries
Nr. of Employees
small (1-50)
Products
Topical heparan sulfate‑mimetic solution for wound and ocular application
Aqueous formulation of a heparan sulfate‑mimicking glycosaminoglycan intended for topical application to chronic wounds, corneal ulcers or surgical sites to promote ECM reconstruction and healing.
Injectable heparan sulfate‑mimetic formulation for systemic delivery
Parenteral formulation administered intramuscularly or intravenously in preclinical and early clinical stroke models to reach ischemic tissues and promote neuroprotection and regeneration.
Topical heparan sulfate‑mimetic solution for wound and ocular application
Aqueous formulation of a heparan sulfate‑mimicking glycosaminoglycan intended for topical application to chronic wounds, corneal ulcers or surgical sites to promote ECM reconstruction and healing.
Injectable heparan sulfate‑mimetic formulation for systemic delivery
Parenteral formulation administered intramuscularly or intravenously in preclinical and early clinical stroke models to reach ischemic tissues and promote neuroprotection and regeneration.
Services
In vivo efficacy testing in rodent and small animal models to evaluate wound closure, angiogenesis, inflammation, collagen synthesis and functional recovery.
Production and characterization of human precision‑cut lung slices for fibrosis and inflammation studies with viability monitoring and functional challenge assays.
Cell migration combined with gene expression assays (RT‑qPCR) using primary pulmonary fibroblasts to assess candidate anti‑fibrotic compounds.
Design and execution of pilot and early‑phase clinical studies in wound healing and regenerative indications, with experience obtaining national regulatory approvals.
In vivo efficacy testing in rodent and small animal models to evaluate wound closure, angiogenesis, inflammation, collagen synthesis and functional recovery.
Production and characterization of human precision‑cut lung slices for fibrosis and inflammation studies with viability monitoring and functional challenge assays.
Cell migration combined with gene expression assays (RT‑qPCR) using primary pulmonary fibroblasts to assess candidate anti‑fibrotic compounds.
Design and execution of pilot and early‑phase clinical studies in wound healing and regenerative indications, with experience obtaining national regulatory approvals.
Expertise Areas
- ECM‑targeted regenerative therapies
- Wound healing and chronic wound management
- Biomaterials design (heparan sulfate mimetics)
- Preclinical disease modeling (wound, ischemia, stroke, periodontitis)
Key Technologies
- Heparan sulfate‑mimetic glycosaminoglycan polymers
- Topical aqueous wound and ophthalmic formulations
- Water‑soluble biodegradable nano‑polymers
- Animal models of diabetic ulcers, ischemia and stroke
News & Updates
OTR3 announces the enrollment of the first patient in a clinical trial for stroke recovery using RGTA® technology.
Approval from ANSM to start a clinical trial with RGTA® in stroke patients.
Research on generating and using human precision-cut lung slices for studying lung diseases.
Establishment of a protocol for generating viable human lung slices for disease modeling.
Research publication on the effects of Cacipliq 20 on post-surgical scars.
Study on how RGTA affects GAG species during muscle development, influencing growth and differentiation.
OTR3 announces the enrollment of the first patient in a clinical trial for stroke recovery using RGTA® technology.
Approval from ANSM to start a clinical trial with RGTA® in stroke patients.
Research on generating and using human precision-cut lung slices for studying lung diseases.
Establishment of a protocol for generating viable human lung slices for disease modeling.
Research publication on the effects of Cacipliq 20 on post-surgical scars.
Study on how RGTA affects GAG species during muscle development, influencing growth and differentiation.